GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » E10

ACAD (ACADIA Pharmaceuticals) E10 : $-1.66 (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was $0.860. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.66 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was -0.60% per year. During the past 5 years, the average E10 Growth Rate was -6.90% per year. During the past 10 years, the average E10 Growth Rate was -6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ACADIA Pharmaceuticals was 26.00% per year. The lowest was -14.00% per year. And the median was -4.20% per year.

As of today (2025-03-14), ACADIA Pharmaceuticals's current stock price is $17.50. ACADIA Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was $-1.66. ACADIA Pharmaceuticals's Shiller PE Ratio of today is .


ACADIA Pharmaceuticals E10 Historical Data

The historical data trend for ACADIA Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals E10 Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -1.63 -1.82 -1.87 -1.66

ACADIA Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.87 -1.86 -1.83 -1.78 -1.66

Competitive Comparison of ACADIA Pharmaceuticals's E10

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Shiller PE Ratio falls into.



ACADIA Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.86/133.1571*133.1571
=0.860

Current CPI (Dec. 2024) = 133.1571.

ACADIA Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -0.400 99.621 -0.535
201506 -0.390 100.684 -0.516
201509 -0.390 100.392 -0.517
201512 -0.450 99.792 -0.600
201603 -0.450 100.470 -0.596
201606 -0.630 101.688 -0.825
201609 -0.610 101.861 -0.797
201612 -0.650 101.863 -0.850
201703 -0.720 102.862 -0.932
201706 -0.550 103.349 -0.709
201709 -0.530 104.136 -0.678
201712 -0.550 104.011 -0.704
201803 -0.440 105.290 -0.556
201806 -0.510 106.317 -0.639
201809 -0.500 106.507 -0.625
201812 -0.500 105.998 -0.628
201903 -0.590 107.251 -0.733
201906 -0.380 108.070 -0.468
201909 -0.290 108.329 -0.356
201912 -0.340 108.420 -0.418
202003 -0.570 108.902 -0.697
202006 -0.270 108.767 -0.331
202009 -0.540 109.815 -0.655
202012 -0.420 109.897 -0.509
202103 -0.420 111.754 -0.500
202106 -0.270 114.631 -0.314
202109 -0.090 115.734 -0.104
202112 -0.270 117.630 -0.306
202203 -0.700 121.301 -0.768
202206 -0.210 125.017 -0.224
202209 -0.170 125.227 -0.181
202212 -0.260 125.222 -0.276
202303 -0.270 127.348 -0.282
202306 0.010 128.729 0.010
202309 -0.400 129.860 -0.410
202312 0.280 129.419 0.288
202403 0.100 131.776 0.101
202406 0.200 132.554 0.201
202409 0.200 133.029 0.200
202412 0.860 133.157 0.860

Add all the adjusted EPS together and divide 10 will get our e10.


ACADIA Pharmaceuticals  (NAS:ACAD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ACADIA Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Executives
Brendan Teehan officer: EVP, COO, Head of Commercial C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer officer: Chief Financial Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara officer: Principal Accounting Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis director, officer: PRESIDENT AND CEO ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Austin D. Kim officer: EVP & General Counsel C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson officer: Executive VP, Research & Dev AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic officer: EVP C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff officer: EVP and CFO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang officer: EVP AND CCO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller officer: Controller & PAO C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130